Author

Patricia Abbe

Inserm

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:metabolism & bioenergetics· 1 Assay:metabolomics· 1

Frequent Co-Authors

Ana Carolina Bastos Sant'Anna SilvaiD· 2 shared Caroline RobertiD· 2 shared Henri MontaudiéiD· 2 shared Issam Ben‐SahraiD· 2 shared Michaël CerezoiD· 2 shared Stéphane RocchiiD· 2 shared Thierry PasseroniD· 2 shared Cyril RoncoiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Ana Carolina Bastos Sant'Anna SilvaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Arginine synthesis pathway and ASS1 play a critical role in mRNA translation reprogramming and ICI resistance in cutaneous melanoma

Emilie Chessel, Wassila Khatir, Ana Carolina Bastos Sant'Anna Silva, Patricia Abbe, Guillaume E. Béranger, Zheyu Ding, Thierry Passeron, Issam Ben‐Sahra, Henri Montaudié, Caroline Robert, Shensi Shen, Stéphane Rocchi, Michaël Cerezo

This study identifies arginine synthesis pathway and ASS1 as key factors in mRNA translation reprogramming and ICI resistance in cutaneous melanoma, showing that targeting ASS1 can restore sensitivity to anti-PD-1.

bioRxiv · Mar 18, 2026 · PreprintCancer Biology

MELK controls tumor metabolism to promote resistance to melanoma therapy

Ana Carolina Bastos Sant'Anna Silva, Patricia Abbe, Sophie Pagnotta, Nívea Dias Amoêdo, Michael D. Torno, Fanny Bonnard, Thomas Botton, Frédéric Larbret, Cyril Ronco, Henri Montaudié, Issam Ben‐Sahra, Caroline Robert, Thierry Passeron, Rodrigue Rossignol, Michaël Cerezo, Stéphane Rocchi

This study identifies MELK as a key driver of metabolic adaptation and therapy resistance in melanoma, showing that inhibiting MELK can sensitize resistant cells to immunotherapy.

bioRxiv · Dec 31, 2025 · PreprintCancer Biology